Current status of clinical trial research and application of immune checkpoint inhibitors for non-small cell lung cancer

Immunotherapy has emerged as a hot topic in the treatment of non-small cell lung cancer (NSCLC) with remarkable success. Compared to chemotherapy patients, the 5-year survival rate for immunotherapy patients is 3-fold higher, approximately 4%–5% versus 15%–16%, respectively. Immunotherapies include...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Fuli, Xia, Teng, Li, Zhiqiang, Gao, Xuzhu, Fang, Xinjian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505960/
https://www.ncbi.nlm.nih.gov/pubmed/37727216
http://dx.doi.org/10.3389/fonc.2023.1213297

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505960/
https://www.ncbi.nlm.nih.gov/pubmed/37727216
http://dx.doi.org/10.3389/fonc.2023.1213297

Ejemplares similares